XELLIA PHARMACEUTICALS ApS: Financial statements 2024
CVR: 61094628
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
XELLIA PHARMACEUTICALS ApS (CVR 61094628) has filed annual accounts for 2024. In 2024, the company reported revenue of DKK 1,599,382,000 and a net result of DKK 828,966,000 compared with DKK -2,384,901,000 the year before. That is a decrease of 19.5% compared with the year before. The profit margin was 51.8%. Equity in the 2024 report amounted to DKK 162,454,000. The solvency ratio was 5.1%. The company had 547 employees in the financial year.
- Revenue
- DKK 1,599,382,000
- Gross Profit
- DKK 37,013,000
- Profit/Loss
- DKK 828,966,000
- Equity
- DKK 162,454,000
- Total Assets
- DKK 3,200,468,000
- Employees
- 547
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | 1.6B | 37M | 829M | 162.5M | 547 |
| 2023 | 2B | -640.2M | -2.4B | -597.8M | 650 |
| 2022 | 2.2B | 318.4M | -371.5M | 1.8B | 648 |
| 2021 | 1.8B | -47M | -503.1M | 2.1B | 640 |
| 2020 | 2B | 361.3M | -115.7M | 2.6B | 624 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
As of September 27, 2024, Michael Uhd has joined the board of directors of XELLIA PHARMACEUTICALS ApS.
As of September 27, 2024, Thomas Clement Guldager has left the board of directors of XELLIA PHARMACEUTICALS ApS.
XELLIA PHARMACEUTICALS ApS has published its annual report for 2023. Revenue came to DKK 1,986,816,000, and the net result was DKK -2,384,901,000.
As of April 11, 2024, Thomas Clement Guldager has joined the board of directors of XELLIA PHARMACEUTICALS ApS.
As of April 11, 2024, John Ramsay Stewart has left the board of directors of XELLIA PHARMACEUTICALS ApS.
About XELLIA PHARMACEUTICALS ApS
XELLIA PHARMACEUTICALS ApS is a Danish company of the type Anpartsselskab based in København S, founded in 1959. The company is registered under the industry Fremstilling af farmaceutiske råvarer. The company was previously named AXELLIA PHARMACEUTICALS ApS and ALPHARMA ApS. The management consists of Michael Kocher. The board consists of Søren Hostrup (chair), Alexander Sebastian Benjamin Sproedt, Hugo Mendes Marques Crespo Dos Reis and Lars Beck Madsen. The company is owned by XELLIA GROUP ApS. The company has 461 employees (2026). In 2025, the company reported revenue of DKK 1,461,516,000 and a net result of DKK 213,738,000 compared with DKK 828,966,000 the year before. Equity in the 2025 report amounted to DKK 404,569,000.
